Patient-derived cancer organoids as a model for predicting clinical response and drug discovery
Lexi Schmitz
Advisor: Dusitn Deming, MD
Utilizing the HiBiT system to identify CARM1 degraders for targeted cancer therapy
Megan Bacabac
Advisor: Wei Xu, PhD